Lab Test

Pancreastatin

Test Codes

MAYO: FPCNS, EPIC: LAB6312, SOFT: XPANC

Instructions

  • Patient must be fasting 10-12 hours prior to collection of specimen.
  • Patient should not be on any medications that may influence Insulin levels, if possible, for at least 48 hours prior to collection.

Specimen Collection Criteria

Collect (preferred specimen): Two Gold-top SST tubes.

Critical frozen. Send specimens for processing immediately after collection.

Physician Office/Draw Specimen Preparation

Critical frozen. Centrifuge to separate serum from cells. Transfer serum to plastic transport tube and freeze (-20°C/-4°F or below) immediately.

Preparation for Courier Transport

Transport: 2.0 mL serum frozen (-20°C/-4°F or below). (Minimum: 1.0 mL)

Rejection Criteria

Specimens not collected and processed as indicated. 

 

In-Lab Processing

Critical frozen. Centrifuge to separate serum from cells. Transfer serum to plastic transport tube and freeze (-20°C/-4°F or below) immediately.

Transport: 2.0 mL serum, frozen (-20°C/-4°F or below). (Minimum: 1.0 mL)

Storage

Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): Unacceptable
Refrigerated (2-8°C or 36-46°F): Unacceptable
Frozen (-20°C/-4°F or below): 30 days

Specimen Storage in Department Prior to Disposal:

Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.

Laboratory

Sent to Mayo Medical Laboratories, Rochester, MN, forwarded to Cambridge Biomedical, Boston, MA.

Performed

Mondays.
Results available within 8-12 days.

Reference Range

By report.

Test Methodology

Enzyme immune assay (EIA)

Interpretation

By report.

Clinical Utility

Pancreastatin is a 49 amino acid peptide produced by degradation of chromogranin A. It inhibits chromogranin A and parathyroid hormone release. Pancreastatin also inhibits release of somatostatin upon glucose stimulation. It may also control carbohydrate metabolism and hyperglycemia. Pancreastatin reduces the early phase of glucose induced insulin release. Suppression of insulin release upon glucose stimulation is a characteristic feature of type-2 diabetes. Pancreastatin could play an important therapeutic role in the treatment of diabetes. Pancreastatin also inhibits the release of somatostatin. It may also control carbohydrate metabolism and hyperglycemia.

CPT Codes

86316

Contacts

Last Updated

5/28/2020

Microtainer® and Vacutainer® are registered trademarks of Becton, Dickinson and Company.
UroVysion® is a registered trademark of Abbott Laboratories. ThinPrep® is a registered trademark of Hologic, Incorporated.

 

This directory currently reflects information only for specimens collected and/or processed at the
Farmington Hills, Grosse Pointe, Royal Oak, and Troy campuses.